Nyxoah SA PE Ratio 2021-2024 | NYXH
Current and historical p/e ratio for Nyxoah SA (NYXH) from 2021 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nyxoah SA PE ratio as of February 07, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nyxoah SA PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-02-07 | 10.65 | 0.00 | |
| 2024-09-30 | 9.55 | $-1.87 | 0.00 |
| 2024-06-30 | 6.97 | $-1.61 | 0.00 |
| 2024-03-31 | 13.49 | $-1.64 | 0.00 |
| 2023-12-31 | 4.64 | $-1.68 | 0.00 |
| 2023-09-30 | 7.05 | $-1.79 | 0.00 |
| 2023-06-30 | 8.01 | $-1.74 | 0.00 |
| 2023-03-31 | 7.47 | $-1.25 | 0.00 |
| 2022-12-31 | 4.99 | $-0.97 | 0.00 |
| 2022-09-30 | 6.30 | $-0.74 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.369B | $0.005B |
| Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $38.872B | 57.28 |
| Tempus AI (TEM) | United States | $10.232B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $8.842B | 224.83 |
| Inspire Medical Systems (INSP) | United States | $5.430B | 169.35 |
| IRhythm Technologies (IRTC) | United States | $3.397B | 0.00 |
| Privia Health (PRVA) | United States | $2.723B | 226.90 |
| Enovis (ENOV) | United States | $2.544B | 16.95 |
| Azenta (AZTA) | United States | $2.469B | 114.98 |
| Clover Health Investments (CLOV) | United States | $2.225B | 0.00 |
| Schrodinger (SDGR) | United States | $1.886B | 0.00 |
| Omnicell (OMCL) | United States | $1.826B | 39.83 |
| 10x Genomics (TXG) | United States | $1.773B | 0.00 |
| Phreesia (PHR) | United States | $1.680B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.937B | 0.00 |
| Talkspace (TALK) | United States | $0.608B | 0.00 |
| Standard BioTools (LAB) | United States | $0.529B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.507B | 0.00 |
| TruBridge (TBRG) | United States | $0.380B | 110.57 |
| Health Catalyst (HCAT) | United States | $0.334B | 0.00 |
| Pulmonx (LUNG) | United States | $0.254B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.233B | 0.00 |
| American Well (AMWL) | United States | $0.176B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.104B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.087B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.073B | 0.00 |
| CareCloud (CCLD) | United States | $0.066B | 0.00 |
| HeartBeam (BEAT) | United States | $0.065B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.045B | 0.00 |
| Outset Medical (OM) | United States | $0.043B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.037B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.022B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.016B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.016B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.005B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |